AU2015221860B2 - TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof - Google Patents

TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof Download PDF

Info

Publication number
AU2015221860B2
AU2015221860B2 AU2015221860A AU2015221860A AU2015221860B2 AU 2015221860 B2 AU2015221860 B2 AU 2015221860B2 AU 2015221860 A AU2015221860 A AU 2015221860A AU 2015221860 A AU2015221860 A AU 2015221860A AU 2015221860 B2 AU2015221860 B2 AU 2015221860B2
Authority
AU
Australia
Prior art keywords
cdkl5
fusion protein
tatk
polypeptide
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015221860A
Other languages
English (en)
Other versions
AU2015221860A1 (en
Inventor
Elisabetta CIANI
Franco Laccone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bologna
Original Assignee
University of Bologna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bologna filed Critical University of Bologna
Publication of AU2015221860A1 publication Critical patent/AU2015221860A1/en
Priority to AU2019219743A priority Critical patent/AU2019219743B2/en
Application granted granted Critical
Publication of AU2015221860B2 publication Critical patent/AU2015221860B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737—C-reactive protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11022—Cyclin-dependent kinase (2.7.11.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2015221860A 2014-02-28 2015-02-27 TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof Active AU2015221860B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019219743A AU2019219743B2 (en) 2014-02-28 2019-08-20 TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461946280P 2014-02-28 2014-02-28
US61/946,280 2014-02-28
PCT/IB2015/000999 WO2015128746A2 (en) 2014-02-28 2015-02-27 Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019219743A Division AU2019219743B2 (en) 2014-02-28 2019-08-20 TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof

Publications (2)

Publication Number Publication Date
AU2015221860A1 AU2015221860A1 (en) 2016-09-08
AU2015221860B2 true AU2015221860B2 (en) 2019-09-12

Family

ID=53539745

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015221860A Active AU2015221860B2 (en) 2014-02-28 2015-02-27 TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof
AU2019219743A Active AU2019219743B2 (en) 2014-02-28 2019-08-20 TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019219743A Active AU2019219743B2 (en) 2014-02-28 2019-08-20 TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof

Country Status (33)

Country Link
US (4) US9290746B2 (enExample)
EP (2) EP3110837B1 (enExample)
JP (2) JP6629747B2 (enExample)
KR (1) KR102307276B1 (enExample)
CN (1) CN106255706A (enExample)
AU (2) AU2015221860B2 (enExample)
BR (1) BR112016019868B1 (enExample)
CA (1) CA2940401C (enExample)
CL (1) CL2016002142A1 (enExample)
CR (1) CR20160392A (enExample)
CY (2) CY1122644T1 (enExample)
DK (2) DK3110837T3 (enExample)
DO (1) DOP2016000220A (enExample)
EA (2) EA038000B1 (enExample)
ES (2) ES2745335T3 (enExample)
HR (2) HRP20191511T1 (enExample)
HU (2) HUE055282T2 (enExample)
IL (2) IL247481B (enExample)
LT (2) LT3110837T (enExample)
MX (2) MX392778B (enExample)
MY (1) MY181566A (enExample)
NI (1) NI201600127A (enExample)
PE (1) PE20161406A1 (enExample)
PH (1) PH12016501689A1 (enExample)
PL (2) PL3110837T3 (enExample)
PT (2) PT3110837T (enExample)
RS (2) RS62244B1 (enExample)
SG (2) SG10202000537RA (enExample)
SI (2) SI3608334T1 (enExample)
SM (2) SMT202100478T1 (enExample)
SV (1) SV2016005264A (enExample)
WO (1) WO2015128746A2 (enExample)
ZA (2) ZA201606655B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055282T2 (hu) * 2014-02-28 2021-11-29 Univ Bologna Alma Mater Studiorum TATK-CDKL5 fúziós fehérjék, készítmények, formulák és azok alkalmazása
US20210268072A1 (en) * 2016-06-28 2021-09-02 Alma Mater Studiorum - Universitá Di Bologna TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof
CN111936624A (zh) * 2017-11-30 2020-11-13 阿米库斯治疗学公司 Cdkl5表达变体和cdkl5融合蛋白
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
WO2021087282A1 (en) * 2019-10-30 2021-05-06 Amicus Therapeutics, Inc. Recombinant cdkl5 proteins, gene therapy and production methods
AU2021218703A1 (en) 2020-02-14 2022-07-28 Ultragenyx Pharmaceutical Inc. Gene therapy for treating CDKL5 deficiency disorder
IT202000025423A1 (it) * 2020-10-27 2022-04-27 Ulisse Biomed S P A Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali
WO2022119890A1 (en) 2020-12-01 2022-06-09 The Trustees Of The University Of Pennsylvania Compositions and uses thereof for treatment of angelman syndrome
CA3229127A1 (en) * 2021-08-18 2023-02-23 Julie Yu Wei Recombinant aav formulations
CN116874571A (zh) * 2021-12-17 2023-10-13 博格隆(上海)生物技术有限公司 突变的蛋白a结构域c及其应用
WO2025050032A1 (en) * 2023-08-31 2025-03-06 Ultragenyx Pharmaceutical Inc. Methods of producing cdkl5 proteins and uses of the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ609640A (en) * 2010-10-25 2015-06-26 Univ D’Aix Marseille Treatment of mecp2-associated disorders
HUE055282T2 (hu) * 2014-02-28 2021-11-29 Univ Bologna Alma Mater Studiorum TATK-CDKL5 fúziós fehérjék, készítmények, formulák és azok alkalmazása

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Anonymous, "Bandi per Assegni di ricerca", (2013-01-01), URL: http://bandi.miur.it/bandi.php/public/fellowship/id_fellow/67724, (2015-08-14) *

Also Published As

Publication number Publication date
IL247481A0 (en) 2016-11-30
ZA201906304B (en) 2022-03-30
DK3110837T3 (da) 2019-09-16
IL275435A (en) 2020-08-31
EP3608334A1 (en) 2020-02-12
LT3110837T (lt) 2019-10-10
RS62244B1 (sr) 2021-09-30
ZA201606655B (en) 2020-05-27
US20160194617A1 (en) 2016-07-07
HUE045393T2 (hu) 2019-12-30
EA038000B1 (ru) 2021-06-22
US9290746B2 (en) 2016-03-22
DK3608334T3 (da) 2021-08-23
PH12016501689B1 (en) 2016-10-03
AU2015221860A1 (en) 2016-09-08
LT3608334T (lt) 2021-11-25
MY181566A (en) 2020-12-29
MX2016011167A (es) 2017-04-06
CR20160392A (es) 2017-06-12
US20180327725A1 (en) 2018-11-15
CA2940401C (en) 2022-11-29
CY1122644T1 (el) 2021-03-12
IL275435B (en) 2021-07-29
MX392778B (es) 2025-03-24
JP2017507655A (ja) 2017-03-23
IL247481B (en) 2020-07-30
PL3110837T3 (pl) 2020-04-30
US10584318B2 (en) 2020-03-10
CY1124727T1 (el) 2022-07-22
CL2016002142A1 (es) 2017-09-08
JP6629747B2 (ja) 2020-01-15
KR102307276B1 (ko) 2021-09-30
SMT202100478T1 (it) 2021-09-14
US10907138B2 (en) 2021-02-02
HUE055282T2 (hu) 2021-11-29
EP3608334B1 (en) 2021-05-19
ES2745335T3 (es) 2020-02-28
DOP2016000220A (es) 2016-12-15
WO2015128746A3 (en) 2015-11-26
KR20170002372A (ko) 2017-01-06
WO2015128746A2 (en) 2015-09-03
AU2019219743B2 (en) 2020-10-29
SI3608334T1 (sl) 2021-11-30
CN106255706A (zh) 2016-12-21
EA202190727A3 (ru) 2021-11-30
EP3110837B1 (en) 2019-06-12
SG11201606863YA (en) 2016-09-29
US20200199549A1 (en) 2020-06-25
JP6896050B2 (ja) 2021-06-30
PT3110837T (pt) 2019-09-12
SG10202000537RA (en) 2020-03-30
SI3110837T1 (sl) 2019-12-31
NI201600127A (es) 2017-03-13
EP3110837A2 (en) 2017-01-04
NZ723371A (en) 2023-11-24
EA201691691A1 (ru) 2017-05-31
SV2016005264A (es) 2017-02-15
SMT201900504T1 (it) 2019-11-13
PT3608334T (pt) 2021-08-25
BR112016019868A2 (pt) 2017-10-17
JP2020062022A (ja) 2020-04-23
PL3608334T3 (pl) 2021-11-22
HRP20191511T1 (hr) 2019-11-29
PH12016501689A1 (en) 2016-10-03
PE20161406A1 (es) 2017-01-14
ES2885245T3 (es) 2021-12-13
BR112016019868B1 (pt) 2023-11-28
HRP20211324T1 (hr) 2021-11-26
MX2020001223A (es) 2022-05-31
CA2940401A1 (en) 2015-09-03
RS59344B1 (sr) 2019-10-31
US9944910B2 (en) 2018-04-17
EA202190727A2 (ru) 2021-07-30
AU2019219743A1 (en) 2019-09-19
US20150247134A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
US10907138B2 (en) TATk-CDKL5 fusion proteins, compositions, formulations, and use thereof
US20210268072A1 (en) TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof
JP2017507655A5 (enExample)
US9616138B1 (en) Cargo carrying nanoparticles
US11603394B2 (en) Targeted effector proteins and uses thereof
EP3496742A1 (en) Peptibodies, compositions thereof, and methods of treating atrial fibrillation
NZ749459A (en) TATĸ-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF
HK1226745A1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)